Cancer Pain Clinical Trial
Official title:
Evaluation of the Medical Service by Socio-aesthetics in Oncology
the 3-year randomized controlled RCT-SE study aims to investigate Socio-aesthetics well being care on quality of life, pain and anxiety. The primary objective is to show that socio-aesthetics well being care improves quality of life during cancer treatment, compared to self care administration of dermo-cosmetics products The secondary objectives are to show that socio-aesthetics well being care significantly reduced anxiety and pain compared to self care administration of dermo-cosmetics products
Socio-aesthetics care is the delivery appropriate beauty care in a population weakened by a physical, psychological and/or social attack. this well-being care is imperfectly assessed with few data from randomized controlled trials. The RCT-STudy is a randomized, controlled, multicenter, open label, intervention study that will be conducted among 400 patients treated with chemotherapy for breast, prostate, colon and lung cancer. Patients will be randomly assigned to one of the two arms of the study according to a 1:1 ratio: - Group A will benefit from 4 sessions of well being care performed by a qualified socio-aesthetic person, with dermo-cosmetics product defined, during 4 consecutive chemotherapy administrations . - Group B (control) will apply the same dermo-cosmetics products themselves (self-care) without intervention of socio-aesthetic, during 4 consecutive chemotherapy administrations 12 Evaluations will be conducted between chemotherapy cure N° 2 and chemotherapy cure N°5: - Pain assessed by Eva - Anxiety assessed by HADS - impact of socio-aesthetics care care , assessed by Patient Centricity Questionnaire (PCQ) (0 -110) Data will be recorded using an e-CRF. patient will be recruited over 3 years and will be followed up for 3 months. Hypothesis: Socio-aesthetics session significantly improves quality of life and reduced pain and anxiety compared to self care administration of dermo-cosmetics products ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03375515 -
PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
|
Phase 3 | |
Recruiting |
NCT03431922 -
Endovascular Denervation in Patients With Cancer Pain
|
N/A | |
Not yet recruiting |
NCT05265052 -
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
|
Phase 2 | |
Withdrawn |
NCT05325164 -
Methadone for 'Adenocarcinopathic' Pain Treatment
|
Phase 3 | |
Completed |
NCT02664987 -
Analgesic Treatment for Cancer Pain in South East Asia
|
N/A | |
Completed |
NCT01946555 -
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
|
N/A | |
Active, not recruiting |
NCT04095234 -
Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT)
|
Phase 2 | |
Recruiting |
NCT05800834 -
Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds
|
Phase 2 | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT02609828 -
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
|
Phase 3 | |
Completed |
NCT03331055 -
PENS or TENS for Pain in Pancreatic Cancer
|
N/A | |
Recruiting |
NCT05506878 -
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
|
N/A | |
Completed |
NCT00766831 -
An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain
|
Phase 4 | |
Recruiting |
NCT05051735 -
PARASTOP - Paracetamol With Strong Opioids
|
Phase 3 | |
Not yet recruiting |
NCT05348174 -
Randomized Controlled Trial of Virtual Reality Assisted Guided Imagery (VRAGI) for Pain in Advanced Cancer Patients.
|
N/A | |
Completed |
NCT05209906 -
An Observation Study to Assess the Efficacy and Safety of Proportional Doses of Painkyl® in Patients With Breakthrough Cancer Pain
|
||
Completed |
NCT03031938 -
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
|
Phase 3 | |
Not yet recruiting |
NCT05594459 -
Early Treatment With Invasive Technique in Cancer Pain Management
|
N/A | |
Withdrawn |
NCT04666623 -
Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
|
Phase 2 | |
Not yet recruiting |
NCT05049811 -
Effects of Mobile Medicine on Cancer Patients
|
N/A |